Unicycive Therapeutics (UNCY) Gains from Investment Securities (2023 - 2026)

Unicycive Therapeutics (UNCY) has 4 years of Gains from Investment Securities data on file, last reported at $4.8 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 157.26% year-over-year to $4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (up 177.62% YoY) and the FY2025 annual result came in at -$2.0 million, down 134.83% from the prior year.
• Gains from Investment Securities retreated to $4.8 million in Q1 2026, from $7.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $12.6 million in Q4 2024 to a low of -$16.8 million in Q2 2024.
• A 4-year average of $1.3 million and a median of -$282000.0 in 2023 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 17602.78% in 2024, down 5860.99% in 2024.
• Tracing UNCY's Gains from Investment Securities over 4 years: stood at -$72000.0 in 2023, then jumped by 17602.78% to $12.6 million in 2024, then slumped by 38.36% to $7.8 million in 2025, then plunged by 38.47% to $4.8 million in 2026.
• The last three Gains from Investment Securities figures came in at $4.8 million (Q1 2026), $7.8 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.